

Ipilimumab (Anti-CTLA-4) Biosimilar In Vivo Antibody (Fc Reduced)

Product Information

Product SKU:

IVMB0218

Size:

500ug

Concentration:

≥ 5.0 mg/ml

Isotype:

Human IgG1 κ ;

Host:

Clone:

MDX-010

Category:

BioSimilar Antibody

Reactivity:

Human

Synonyms:

CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3

Specificity:

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.

Formulation:

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or



preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Endotoxin Level:

< 1.0 EU/mg as determined by the LAL method

Purity:

>95% monomer by analytical SEC

Immunogen:

Storage and Stability:

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Product Preparation:

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Applications

B, CyTOF®, ELISA, FC

Applications & Recommended Usage:

B, CyTOF®, ELISA, FC